A double blind, placebo-controlled trial of the NMDA glycine site antagonist, gw468816, for prevention of relapse to smoking in females / A. Eden Evins en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 5 (Octubre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 5 (Octubre) . - pp. 597-602 Título : A double blind, placebo-controlled trial of the NMDA glycine site antagonist, gw468816, for prevention of relapse to smoking in females Tipo de documento: texto impreso Autores: A. Eden Evins, Autor ; Gladys Pachas, Autor ; David Mischoulon, Autor Fecha de publicación: 2022 Artículo en la página: pp. 597-602 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Nicotina, Dejar de fumar, NMDA, Glutamato, Prevención de recaídas, Glicina Resumen: Relapse to smoking is common after initial abstinence with pharmacotherapy and behavioral support and represents a major clinical challenge. Although mechanisms underlying relapse to smoking have not been elucidated, preclinical studies suggest that glutamate receptors may be involved. Link: ./index.php?lvl=notice_display&id=29355 [artículo] A double blind, placebo-controlled trial of the NMDA glycine site antagonist, gw468816, for prevention of relapse to smoking in females [texto impreso] / A. Eden Evins, Autor ; Gladys Pachas, Autor ; David Mischoulon, Autor . - 2022 . - pp. 597-602. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 5 (Octubre) . - pp. 597-602 Palabras clave: Nicotina, Dejar de fumar, NMDA, Glutamato, Prevención de recaídas, Glicina Resumen: Relapse to smoking is common after initial abstinence with pharmacotherapy and behavioral support and represents a major clinical challenge. Although mechanisms underlying relapse to smoking have not been elucidated, preclinical studies suggest that glutamate receptors may be involved. Link: ./index.php?lvl=notice_display&id=29355

---

1 (1 - 1 / 1)